top of page
Search

** Updates to our COVID-19 management guidelines **

Writer: Miraal MavalvalaMiraal Mavalvala

In anticipation of a possible surge in hospitalizations and taking into account recent evidence, (and limited supplies of some therapeutics) we are delighted to present our revised (v9) guidelines! Main changes compared to previous version are highlighted in "SUMMARY of changes" . As always, these guidelines are the product of thoughtful discussions between ID and pharmacy experts, with input from a multidisciplinary group of colleagues.


HAPPY HOLIDAY SEASON to all, from the ASP team!!



 
 
 

Recent Posts

See All

Linezolid TDM

INESSS approved the TDM of Linezolid in May 2024 It is now available in the MUHC (via HSJ labs) The ASP committee is happy to publish a...

MUHC ASP annual report 2022-2023

The ASP chairs are happy to publish the MUHC ASP annual report 2022-2023, now available in the Resources section of the MUHC ASP website....

S.aureus bacteremia

The ASP committee is happy to give you an early Christmas gift! We published the guidelines on management and treatment of Staphylococcus...

Commentaires


+1 514-934-1934

1001 Decarie Blvd, Montreal, Quebec H4A 3J1, Canada

bottom of page